Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
Rhea-AI Summary
Creative Medical Technology (Nasdaq: CELZ) entered agreements for the immediate exercise of up to 2,790,340 warrants at a reduced exercise price of $1.60 per share, generating expected gross proceeds of about $4.5 million before fees.
The company will issue new unregistered warrants for up to 5,580,680 shares at $1.60, exercisable for five years after shareholder approval. Closing is expected on June 30, 2026, with net proceeds intended for working capital and general corporate purposes.
Positive
- Approximately $4.5 million in expected gross cash proceeds from warrant exercises
- Immediate exercise of up to 2,790,340 previously issued warrants at $1.60 per share
- Use of net proceeds earmarked for working capital and general corporate purposes
Negative
- Issuance of new warrants for up to 5,580,680 additional shares, creating potential dilution
- New warrants and underlying shares initially unregistered, requiring future resale registration
- Reduced exercise price on existing warrants may imply value transfer from existing shareholders
News Market Reaction – CELZ
On the day this news was published, CELZ gained 78.97%, reflecting a significant positive market reaction. Argus tracked a peak move of +413.6% during that session. Our momentum scanner triggered 76 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $16.90M at that time. Trading volume was exceptionally heavy at 515.2x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 29 | Warrant exercise financing | Negative | -32.7% | Inducement warrant exercises raising $4.2M and issuing new 2.79M-share warrants. |
| Mar 06 | Warrant exercise financing | Negative | -29.3% | Immediate warrant exercises for $3.7M gross proceeds plus new 1.67M-share warrants. |
| Oct 23 | Registered direct offering | Negative | -22.6% | At-the-market $1.85M direct offering with concurrent 837K-share warrant issuance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past financing and warrant-exercise announcements for CELZ have consistently triggered large single-day share price declines.
Key Terms
warrants financial
form s-3 regulatory
private placement financial
registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedic, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of
Roth Capital Partners is acting as the Company’s financial advisor for this transaction.
In consideration for the immediate exercise of the existing warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 5,580,680 shares of common stock, at an exercise price of
The transaction is expected to close on June 30, 2026. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a biotechnology company focused on regenerative and immunotherapy-based treatments, with programs spanning immunotherapy, endocrinology, urology, neurology, and orthopedic.
Forward-Looking Statements
This news release may contain forward-looking statements, including but not limited to comments regarding the closing of the offering and the use of proceeds therefrom, the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions, which may involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
